The efficacy and safety of P in combination with the receptor tyrosine kinase inhibitor (TKI) cabozantinib with activity against a broad range of targets, such as MET, RET, AXL, VEGFR2, FLT3, and c-KIT was evaluated in a phase II study in 36 R/M HNSCC (4 LSCC patients were enrolled). This evidence concerns the gene RET and head and neck squamous cell carcinoma.